Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.
Marco Antonio MascarellaTolani F OlonisakinPurva H RumdeVarun VendraMelonie A NanceSeungwon KimMark W KubikShaum S SridharanMatthew J FerrisMoon J FentonDaniel R ClayburghJames P OhrSonali C JoyceMalabika SenJames G HermanJennifer R GrandisDan P ZandbergUmamaheswar DuvvuriPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Brief neoadjuvant therapy achieved pathologic downstaging in a subset of patients and was associated with significantly better DFS and OS as well as decreased circulating methylated SOX17 and TAC1.
Keyphrases
- locally advanced
- rectal cancer
- end stage renal disease
- lymph node
- ejection fraction
- newly diagnosed
- chronic kidney disease
- stem cells
- neoadjuvant chemotherapy
- prognostic factors
- peritoneal dialysis
- transcription factor
- radiation therapy
- patient reported outcomes
- mesenchymal stem cells
- bone marrow
- free survival
- smoking cessation